González BSL, Vargas GDJ, Castillo BY, López FCC

Language: Spanish
References: 15
Page: 184-192
PDF size: 502.25 Kb.

ABSTRACT

Bisphosphonates are drugs widely used in the treatment of bone diseases such as osteoporosis and osteopenia due to their ability to inhibit bone resorption. However, their prolonged use without continuous medical monitoring is associated with significant adverse effects, osteonecrosis of the jaws, a serious condition that affects both oral and general health, among them. In addition, a possible association of these drugs with an increased risk of developing periodontal disease has been noted, highlighting the importance of comprehensive care for this patient population. This article presents the clinical case of a patient who has been undergoing bisphosphonate therapy for more than a decade, it analyzes the dental complications derived from its use and its impact on quality of life. Within the context of bone remodeling, the challenges associated with the prevention and management of these complications are discussed, emphasizing the need for thorough dental evaluations prior to and during bisphosphonate therapy.Moreover, the article underscores the importance of fostering close collaboration between physicians and dentists to enable joint efforts in implementing preventive strategies and providing appropriate management of side effects. Active surveillance, along with increased knowledge and understanding among healthcare professionals, is essential to ensure the safety and well-being of patients under bisphosphonate treatment, thereby promoting a multidisciplinary and preventive approach to care.

REFERENCES

1. Pazmiño VFC, Assem NZ, Pellizzer EP, DeAlmeida JM, Theodoro LH. Influencia delestrógeno en la enfermedad periodontal: revisión deliteratura. Av En Periodoncia E Implantología Oral. 2015;27(2):75-8.

2. Monte FMM, Furtado MAM. Bisfosfonatos eosteonecrose maxilar: uma revisão narrativa daliteratura [Internet]. Res Soc Dev. 2023;12(4).[citado 17 julio 2025]. Disponible en:http://dx.doi.org/10.33448/rsd-v12i4.41166

3. Pérez B, Sacramento M. Osteonecrosis de losmaxilares asociada a bisfosfonatos. Med Oral PatolOral Cir Bucal. 2009;14(1):32-5.

4. Vargas Casillas AP, Yáñez Ocampo BR.Clasificación de enfermedades y condicionesperiodontales y periimplantarias 2018. Primeraparte [Internet]. Rev Odontol Mex UNAM.2022;25(1):10‑26. [citado 17 julio 2025].Disponible en:https://doi.org/10.22201/fo.1870199xp.2021.25.1.82268

5. Gómez Rea IA, Rizo Méndez V, RodriguezChávez I, Venegas Navarro MEN. Manejoodontológico de pacientes tratados con bifosfonatos:Una revisión sistemática. Rev LatinoamDifus Científica. 2024; 6(10):29-44.

6. Bejar CR, Félix VMC. Protocolo clínico depacientes con historia de uso de bifosfonatos. RevADM. 2017; 74(5):252-60.

7. López Lastra JC, López Noriega JC, RuizRodríguez R, González Reyes M. Osteonecrosis delos maxilares inducida por medicamentos: reportede un caso y revisión de la literatura. Rev Mex CirBucal Maxilofac. 2023; 19(1):29-40.

8. Lorz Ulloa P, Varela Guillén R. La prueba CTXcomo evaluador de riesgo en el diagnóstico ytratamiento de osteonecrosis de los maxilaresinducida por el uso de bifosfonatos. Odovtos - Int JDent Sci. 2015; 17(1):41.

9. Filella X, Guañabens N. Utilidad clínica de losbiomarcadores óseos: un desafío a la variabilidad[Internet]. Adv Lab Med. 2023;5(1):15‑23. [citado17 julio 2025]. Disponible en:https://doi.org/10.1515/almed-2023-0041

10. Fernández, E., Padilla, P., Reyes Ch., Lisboa, D.Osteonecrosis mandibular relacionada conmedicamentos: conceptos teóricos y prácticosactuales para el odontólogo general. OdontologíaVital. 2018; 29:19-32.

11. Cummings SR, Santora AC, Black DM, RussellRGG. History of alendronate [Internet]. Bone.2020;137:115411. [citado 17 julio 2025].Disponible en:https://doi.org/10.1016/j.bone.2020.115411

12. Vidal MA, Medina C. Seguridad de losbifosfonatos. Rev Soc Esp Dolor SED. 2011;18(1):43-55.

13. Kohli A, Pezzotto SM, Poletto L. Hipercementosis Apicales y No Apicales en RaícesDentarias Humanas. Int J Morphol. 2011;29(4):1263-7.

14. Vinitzky-Brener I, Ibáñez-Mancera NG,Álvarez Jardón AP, Serra-Rico LJ, Carrasco RuedaCA, Fernández Plata R, et al. Conocimiento yconciencia de los médicos sobre la osteonecrosisrelacionada con bifosfonatos. Rev Asoc Dent Mex. 2021; 78(1):28-32.

15. Sanz M, Herrera D, Kebschull M, Chapple I,Jepsen S, Berglundh T, et al. Treatment of stage I–III periodontitis—The EFP S3 level clinical practiceguideline. J Clin Periodontol. 2020; 47 (Suppl22):4-60.